Ready-to-Use Formulation of Zosyn Injection Now Available

Credit: Baxter.
Zosyn premix is supplied in 2.25g in 50mL, 3.375g in 50mL, and 4.5g in 100mL presentations.

Baxter has announced the launch of a frozen premix formulation of Zosyn (piperacillin and tazobactam) Injection.

The ready-to-use formulation consists of piperacillin, a penicillin-class antibacterial, and tazobactam, a beta-lactamase inhibitor, for intravenous administration. The product is indicated for the treatment of multiple infections caused by susceptible bacteria, including intra-abdominal infections, nosocomial pneumonia, skin and skin structure infections, female pelvic infections, and community-acquired pneumonia.

“Zosyn premix is an important addition to Baxter’s portfolio of valuable anti-infective medications that help treat some of the most pressing health care needs facing patients today,” said Alok Sonig, executive vice president and group president, Pharmaceuticals, at Baxter. “We are thrilled to provide an additional frozen premix option that can help support patient safety and offer added convenience for health care providers.”

Zosyn premix is supplied in 2.25g in 50mL, 3.375g in 50mL, and 4.5g in 100mL presentations in Galaxy containers (non-PVC and non-DEHP system). If the dose required does not equal 2.25g, 3.375g, or 4.5g, using Zosyn injection in Galaxy containers is not recommended and an alternative formulation of Zosyn should be considered.


  1. Baxter launches Zosyn premix in US. News release. Baxter. Accessed April 4, 2023.
  2. Package insert. Baxter; 2023. Accessed April 4, 2023.